<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03808805</url>
  </required_header>
  <id_info>
    <org_study_id>ApHyPAP 29BRC18.0036</org_study_id>
    <nct_id>NCT03808805</nct_id>
  </id_info>
  <brief_title>Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms</brief_title>
  <acronym>APHYPAP</acronym>
  <official_title>Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies
      APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and
      suffering of persistent aquagenic pruritus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Identification of patients with myeloproliferative neoplasms and aquagenic pruritus.
      Evaluation of the intensity of the aquagenic pruritus. Patients with value &gt;5/10 on the VAS
      (Visual Analogue Scale ) are proposed to participate to the protocole. Randomization between
      the two treatments. Duration of the treatment : 14 days. Regular evaluation of efficacity of
      the drugs (questionnaires). Evaluations will stop 2 months after the last intake. Blood
      samples will be collected before and after the intakes to study cytokine and neuropeptide
      levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 3, randomized prospective study, double blind-double placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale )</measure>
    <time_frame>at 15 days</time_frame>
    <description>number of patients with a pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale )</measure>
    <time_frame>at 60 days</time_frame>
    <description>number of patients with a pruritus intensity below (or equal) 3/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cessation of pruritus</measure>
    <time_frame>at 15 days</time_frame>
    <description>number of patients with a pruritus intensity at 0/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms) )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cessation of pruritus</measure>
    <time_frame>at 60 days</time_frame>
    <description>number of patients with a pruritus intensity at 0/10 on the VAS (Visual Analogue Scale wich measure the intensity of symptoms of pruritus, 0 is minimum and 10 is maximum intensity of symptoms))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time observed to decreased the VAS to 3/10</measure>
    <time_frame>01 to 60 days</time_frame>
    <description>number of days to obtain an intensity of pruritus at 3/10 on the VAS (Visual Analogue Scale )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment effectiveness</measure>
    <time_frame>1 to 60 days</time_frame>
    <description>number of days the VAS (Visual Analogue Scale ) is below (or equal) 3/10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event occurring during the association therapeutic</measure>
    <time_frame>at 15 days</time_frame>
    <description>type of adverse event occuring during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of prematurely discontinued anti-pruritic treatment</measure>
    <time_frame>at 15 days</time_frame>
    <description>Total number of prematurely discontinued treatments for all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete blood count (normal or abnormal)</measure>
    <time_frame>1 to 60 days</time_frame>
    <description>number of patients with hematologic remission : hematocrit &lt;45% with leukocytes &lt;10 giga/l and platelets &lt;400 giga/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life through the use of validated questionnaire : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire</measure>
    <time_frame>at J0 (day of inclusion)</time_frame>
    <description>Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire</measure>
    <time_frame>at J0 (day of inclusion)</time_frame>
    <description>Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life through the use of validated questionnaire : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire</measure>
    <time_frame>at 15 days</time_frame>
    <description>Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers)questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire</measure>
    <time_frame>at 15 days</time_frame>
    <description>Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life through the use of validated questionnaires : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire</measure>
    <time_frame>at 30 days</time_frame>
    <description>Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire</measure>
    <time_frame>at 30 days</time_frame>
    <description>Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life through the use of validated questionnaire : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire</measure>
    <time_frame>at 45 days</time_frame>
    <description>Evaluation of quality of life by completion of the MPN-SAF(Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire</measure>
    <time_frame>at 45 days</time_frame>
    <description>Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life through the use of validated questionnaire : the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form) questionnaire</measure>
    <time_frame>at 60 days</time_frame>
    <description>Evaluation of quality of life by completion of the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form calculated as the mean score for 10 items. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life through the use of validated questionnaire : the PASYMPLE questionnaire</measure>
    <time_frame>at 60 days</time_frame>
    <description>Evaluation of quality of life by completion of the PASYMPLE (evaluation of pruritus with 7 questions about occurence, timing, intensity and localisation of pruritus) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the change of plasma concentrations of cytokines and neuropeptides</measure>
    <time_frame>at J0 (day of inclusion)</time_frame>
    <description>Plasma concentrations of cytokines (ng/L) and neuropeptides (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the change of plasma concentrations of cytokines and neuropeptides</measure>
    <time_frame>at 15 days</time_frame>
    <description>Plasma concentrations of cytokines (ng/L) and neuropeptides (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the change of plasma concentrations of cytokines and neuropeptides</measure>
    <time_frame>at 30 days</time_frame>
    <description>Plasma concentrations of cytokines (ng/L) and neuropeptides (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the change of plasma concentrations of cytokines and neuropeptides</measure>
    <time_frame>at 60 days</time_frame>
    <description>Plasma concentrations of cytokines (ng/L) and neuropeptides (ng/mL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Myeloproliferative Disorder</condition>
  <condition>Aquagenic Pruritus</condition>
  <arm_group>
    <arm_group_label>studied group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant 80 mg daily - 14 days Plus placebo of Hydroxyzine - 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>comparative group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxyzine 25 mg/d - 14 days Plus placebo of Aprepitant - 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant 80 mg</intervention_name>
    <description>oral therapy - daily dose - 14 days</description>
    <arm_group_label>studied group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyzine 25mg</intervention_name>
    <description>oral therapy - daily dose - 14 days</description>
    <arm_group_label>comparative group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Hydroxyzine</intervention_name>
    <description>oral therapy - daily dose - 14 days</description>
    <arm_group_label>studied group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Aprepitant</intervention_name>
    <description>oral therapy - daily dose - 14 days</description>
    <arm_group_label>comparative group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major patients with myeloproliferative neoplasms (polycythemia vera, essential
             thrombocythaemia or myelofibrosis)

          -  and treated with hydroxyurea, pipobroman, anagrelide, α2a pegylated interferon,
             ruxolitinib or bled for more than 6 months

          -  and suffering of persistent aquagenic pruritus

          -  and with a pruritus intensity on Analogic Visual Scale &gt;5/10

          -  patients who gave their written consent for participation in the study

        Exclusion Criteria:

          -  patients with a physical or psychological disability to sign the consent form

          -  patients with myeloproliferative neoplasms and suffering of aquagenic pruritus but
             only treated by aspirin

          -  patients already included in another therapeutic protocol

          -  patients with diffuse dermatological disease where pruritus may be present (psoriasis,
             atopic dermatitis, prurigo

          -  patients already on anti-anxiety and / or anti-depressant treatment

          -  patients with absolute contraindications to the use of Aprepitant or Hydroxyzine

          -  hypersensitivity to Aprepitant and / or Hydroxyzine or to any of their excipients

          -  lactose intolerance

          -  pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe IANOTTO, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hématologie Clinique-Institut de Cancéro-Hématologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Christophe IANOTTO, MD, PhD</last_name>
    <phone>02 98 22 37 86</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-christophe.ianotto@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Brest - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <state>Brest Cedex</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe IANOTTO, Dr</last_name>
      <phone>02 98 22 37 86</phone>
      <email>jean-christophe.ianotto@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise BOYER, Dr</last_name>
      <phone>02 41 35 54 50</phone>
      <email>FrBoyer-Perrard@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Douarnenez</name>
      <address>
        <city>Douarnenez</city>
        <zip>29171</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Sophie LE BRIS-MICHEL, Dr</last_name>
      <phone>02 98 75 15 85</phone>
      <email>as.lebris@ch-douarnenez.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier des Pays de Morlaix</name>
      <address>
        <city>Morlaix</city>
        <zip>29672</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohamed MALOU, Pr</last_name>
      <phone>02 98 62 60 38</phone>
      <email>mmalou@ch-morlaix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cornouaille</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal HUTIN, Dr</last_name>
      <phone>02 98 52 61 50</phone>
      <phone_ext>+33</phone_ext>
      <email>p.hutin@ch-cornouaille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Yves Le Foll</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22027</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iuliana MARTINIUC</last_name>
      <phone>02 96 01 75 87</phone>
      <email>iuliana.martiniuc@ch-stbrieuc.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>January 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Hydroxyzine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

